Nicolas Gourdin Selected Research

Adenosine Triphosphate (ATP)

1/2019

Blocking Antibodies Targeting the CD39/CD73 Immunosuppressive Pathway Unleash Immune Responses in Combination Cancer Therapies.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Nicolas Gourdin Research Topics

Disease

5	Neoplasms (Cancer) 10/2023 - 01/2018
1	Ovarian Neoplasms (Ovarian Cancer) 10/2023
1	Disease Progression 10/2023
1	Acute Myeloid Leukemia (Acute Myelogenous Leukemia) 01/2023
1	Breast Neoplasms (Breast Cancer) 11/2021

Drug/Important Bio-Agent (IBA)

4	Immune Checkpoint InhibitorsIBA 10/2023 - 01/2018
1	Netrin-1IBA 10/2023
1	Interleukin-3 Receptors (Interleukin 3 Receptor)IBA 01/2023
1	Interleukin-2 Receptors (IL 2 Receptor)IBA 10/2022
1	AntigensIBA 10/2022
1	Proteins (Proteins, Gene)FDA Link 11/2021
1	Blocking AntibodiesIBA 01/2019
1	Oxaliplatin (Eloxatin)FDA LinkGeneric 01/2019
1	Adenosine Triphosphate (ATP)IBA 01/2019
1	AntibodiesIBA 01/2019
1	Monoclonal AntibodiesIBA 01/2019
1	Adenosine Triphosphatases (ATPase)IBA 01/2018
1	Adenosine (Adenocard)FDA LinkGeneric 01/2018
1	beta-apocarotenoid-14',13'-dioxygenase (ADO)IBA 01/2018

Therapy/Procedure

4	Therapeutics 10/2023 - 01/2018
2	Immunotherapy 10/2023 - 10/2022
2	Drug Therapy (Chemotherapy) 10/2023 - 01/2019